Table 3. Response assessment by PET and MRI.
| Patient | Age | PS | Cs | PETd | MRI2 | PET2 | MRI4 | PET4 | MRIe | PETe | FU | Events |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 64 | 0 | EA | 19,6 | CRu | N | CR | N | CR | N | 43+ | RE, SAL, ASCT |
| 2 | 39 | 1 | EA | 14 | PR | N | ND | N | CR | N | 32+ | - |
| 3 | 77 | 2 | EA | 29,2 | PR | N | CR | N | CR | N | 29+ | - |
| 4 | 60 | 0 | EA | r | CR | N | CR | N | CR | N | 29+ | - |
| 5 | 69 | 2 | EA | 22,6 | CRu | N | CR | N | CR | N | 40+ | - |
| 6 | 78 | 3 | - | 50 | ND | N | Cru | N | CR | N | 33+ | - |
| 7 | 66 | 2 | EA | 21,6 | PR | N | ND | N | CR | N | 31+ | - |
| 8 | 78 | 3 | RT | 8,5 | PR | N | ND | ND | CR | ND | 26+ | - |
| 9 | 60 | 1 | EA | 19 | ND | N | Cru | N | CR | N | 29+ | - |
| 10 | 80 | 0 | - | r | CR | N | CR | N | ND | ND | 15 | Ocular progression, SAL, LRD |
| 11 | 77 | 0 | RT | 23,2 | CRu | N | CR | N | CR | N | 24+ | - |
| 12 | 75 | 2 | RT | 8,3 | ND | N | CR | N | CR | N | 19 | Death (lung cancer) |
| 13 | 79 | 2 | RT | 24,6 | ND | N | CR | N | CR | N | 24+ | - |
| 14 | 59 | 2 | EA | 32,9 | CRu | N | CR | N | CR | N | 19+ | - |
| 15 | 83 | 3 | - | r | CR | N | CR | N | CR | N | 32+ | Pulmonary embolism |
| 16 | 47 | 2 | EA | 24,7 | PR | N | CR | N | CR | N | 15+ | - |
| 17 | 58 | 2 | EA | r | CR | N | CR | N | CR | N | 11 | RE, LRD |
| 18 | 63 | 1 | EA | r | CR | N | CR | N | CR | N | 11+ | - |
| 19 | 68 | 3 | - | 21,6 | CRu | N | ND | N | ND | ND | 4 | Death (suicide) |
| 20 | 71 | 1 | EA | 13,8 | PR | P | Cru | N | CR | N | 42+ | - |
| 21 | 57 | 3 | - | 34,7 | PR | P | PD | P | ND | ND | 34+ | SAL, ASCT |
| 22 | 78 | 2 | - | 32,4 | SD | P | ND | ND | ND | ND | 6 | LRD |
| 23 | 79 | 1 | - | 18,8 | SD | P | ND | ND | ND | ND | 12 | LRD |
| 24 | 66 | 1 | - | 33,2 | PD | P | ND | ND | ND | ND | 10+ | SAL, ASCT |
| 25 | 57 | 0 | EA | 63 | CRu | P | CR | N | CR | N | 11+ | - |
PS: ECOG performance status; Cs: consolidation; PETd: PET at diagnosis (SUVmax); MRI2: MRI after 2 RMT cycles; PET2: PET after 2 RMT cycles; MRI4: MRI after 4 cycles; PET4: PET after 4 cycles; MRIe: MRI at the end of treatments; PETe: PET at the end of treatments; FU: follow-up (months); r: complete surgical resection; ND: not done; EA: etoposide cytarabine; ASCT : autologous stem cell transplantation; RT: radiotherapy; SAL : Salvage therapy; SD: stable disease; PD: progressive disease; PR : partial response; CR: complete remission; CRu: complete remission unknown; N: negative; P: positive; +: alive; RE: relapse; LRD: lymphoma-related death.